Date published: 2026-7-28

1-800-457-3801

SCBT Portrait Logo
Seach Input

Atracurium Besylate (CAS 64228-81-5)

5.0(1)
Write a reviewAsk a question

See product citations (3)

Alternate Names:
2,2′-[1,5-Pentanediylbis[oxy(3-oxo-3,1-propanediyl)]]bis[1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-isoquinolinium Benzenesulfonate; Atracurium Dibesylate; BW 33A; Tracrium; Tracur; Wellcome 33A74
Application:
Atracurium Besylate is a neuromuscular blocking agent
CAS Number:
64228-81-5
Purity:
≥98%
Molecular Weight:
1243.48
Molecular Formula:
C65H82N2O18S2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.

QUICK LINKS

Atracurium besylate is a benzylisoquinoline compound that acts as a neuromuscular blocking agent, causing a non-depolarizing block at the neuromuscular junction. It exhibits a slow onset and intermediate duration of action. Atracurium besylate, the bisbenzenesulfonate salt of atracurium, plays a role as a muscle relaxant and nicotinic antagonist. As a quaternary ammonium salt and an organosulfonate salt, it contains atracurium.


Atracurium Besylate (CAS 64228-81-5) References

  1. Neuromuscular and cardiovascular effects of atracurium in isoflurane-anesthetized chickens.  |  Nicholson, A. and Ilkiw, JE. 1992. Am J Vet Res. 53: 2337-42. PMID: 1476319
  2. Pharmacokinetics and neuromuscular blocking effects of atracurium besylate and two of its metabolites in patients with normal and impaired renal function.  |  Vandenbrom, RH., et al. 1990. Clin Pharmacokinet. 19: 230-40. PMID: 2394062
  3. Physical compatibility and chemical stability of atracurium besylate and midazolam hydrochloride during intravenous coinfusion.  |  Bhatt-Mehta, V. and Hirata, S. 1998. Int J Pharm Compd. 2: 79-82. PMID: 23989485
  4. Pharmacokinetics of atracurium besylate in the pig after a single i.v. injection.  |  Schopfer, C., et al. 1989. Eur J Drug Metab Pharmacokinet. 14: 299-302. PMID: 2633924
  5. Atracurium Besylate and other neuromuscular blocking agents promote astroglial differentiation and deplete glioblastoma stem cells.  |  Spina, R., et al. 2016. Oncotarget. 7: 459-72. PMID: 26575950
  6. Simultaneous determination of atracurium besylate and its major decomposition products and related impurities by reversed-phase high-performance liquid chromatography.  |  Nehmer, U. 1988. J Chromatogr. 435: 425-33. PMID: 3356756
  7. The effects of atracurium besylate (Tracrium) on intracranial pressure and cerebral perfusion pressure.  |  Rosa, G., et al. 1986. Anesth Analg. 65: 381-4. PMID: 3754098
  8. The screening of atracurium in MHS swine.  |  Morrell, DF. and Harrison, GG. 1986. Br J Anaesth. 58: 444-6. PMID: 3754146
  9. The pharmacokinetics and pharmacodynamics of atracurium in patients with and without renal failure.  |  Fahey, MR., et al. 1984. Anesthesiology. 61: 699-702. PMID: 6239574
  10. Atracurium besylate in paediatric anaesthesia.  |  Lavery, GG. and Mirakhur, RK. 1984. Anaesthesia. 39: 1243-6. PMID: 6549107
  11. Pharmacokinetics of atracurium besylate in healthy patients (after a single i.v. bolus dose).  |  Ward, S., et al. 1983. Br J Anaesth. 55: 113-8. PMID: 6687550
  12. Determination of atracurium besylate in human plasma.  |  Neill, EA. and Jones, CR. 1983. J Chromatogr. 274: 409-12. PMID: 6688255
  13. Clinical evaluation of atracurium besylate requirement for a stable muscle relaxation during surgery: lack of age-related effects.  |  d'Hollander, AA., et al. 1983. Anesthesiology. 59: 237-40. PMID: 6688332
  14. Chemical stability and adsorption of atracurium besylate injections in disposable plastic syringes.  |  Pramar, YV., et al. 1996. J Clin Pharm Ther. 21: 173-5. PMID: 8873851

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

Atracurium Besylate, 10 mg

sc-210845
10 mg
$84.00